Genoscience Pharma announces launch of phase 2b clinical trial of ezurpimtrostat (GNS561) to treat hepatocarcinoma in combination with an immune checkpoint inhibitor and an antiangiogenic agent
- First patient received initial treatment on January 2
- Addition of ezurpimtrostat to standard first-line treatment makes it possible to sensitize tumor to activity of immune checkpoint inhibitors
- First-line trial for treatment of hepatocellular carcinoma marks a turning point in development of Genoscience Pharma
Marseille, France, January 6, 2023 –Genoscience Pharma, a clinical-stage biotech company developing unique lysosomotropic drug candidates for the treatment of cancer, fibrosis and auto-immune diseases through autophagy modulation, along with trial sponsor Grenoble University Hospital, today announce the launch of the ABE-LIVER study. This phase 2b clinical trial will focus on first-line treatment of HepatoCellular Carcinoma (HCC) patients with Genoscience Pharma’s drug candidate ezurpimtrostat (GNS561). This is administered in conjunction with standard atezolizumab/bevacizumab treatment. The first patient received the initial treatment on January 2. Genoscience Pharma is providing ezurpimtrostat and operational support.
